INTRODUCTION
============

Monoamine oxidase (MAO) is an important enzyme to metabolize *in vivo* endogenous and diet-derived biogenic amines via oxidative deamination. Major substrates are noradrenaline, adrenaline, dopamine, β-phenylethylamine (PEA) and serotonin. These substrates are underlying in the biochemical pathology of \"depression\" and Parkinson\'s disease (PD). The deficiency of serotonin, noradrenaline and dopamine builds-up the hypothesis of \"depression\" while a loss of dopamine, noradrenaline and serotonin is the biochemical basis of degenerative processes underlying PD. Therefore, supplementation of deficient biogenic amine neurotransmitters with 3,4-dihydroxy-phenylalanin (L-DOPA) has been established as early as the late 50^th^ and early 60^th^ of the last century including the use of MAO-inhibitors. This class of psychopharmacological active compounds inhibits the break-down of biogenic amine neurotransmitters and thus increase their concentration in the synaptic cleft and at respective postsynaptic receptor sites. A mood elevating effect in patients with tuberculosis after treatment with iproniazid was first described by Kline ([@B73]). In PD the first reports were published by Sano ([@B138]; [@B53]) using iproniazid and pheniprazine alone or in combination with D,L-DOPA in a small number of patients, Degkwitz et al. ([@B39]), who used iproniazid in combination with L-DOPA and in reserpin treated patients with schizophrenia and Birkmayer, Hornykiewicz and Bernheimer, who tried a variety of compounds like harmine, isocarboxazid and other MAO-I\'s ([@B14]; [@B18]; [@B16]; [@B17]) alone or in combination with L-DOPA in PD. The effects were mild or not existing when these MAO-I were given alone. However all theses early reports agree that MAO-I potentiated the effect of (D), L-DOPA but intensified also adverse reactions. Further examination and post mortem studies gave evidence that MAO-I given shortly before patients deaths were restoring the levels of noradrenaline and serotonin with no significant effect on the concentration of brain dopamine ([@B12]; [@B13]). This data pointed to a combination therapy of L-DOPA and MAO-I already in the early 60^th^ of the last century. An extensive description of detailed historical aspects of MAO and its inhibitors is given in the excellent overview on treatment strategies in PD by Foley ([@B52]). A further break-through was the discovery of multiple forms of MAO, MAO-A and MAO-B, by Johnston ([@B71]). MAO-A deaminates especially serotonin, noradrenaline and tyramine and is inhibited selectively at low concentrations (µM) of clorgyline while MAO-B is insensitive to clorgyline and in the human brain desaminates PEA and to a high degree dopamine ([@B60]). The first selective MAO-B-I was L-deprenyl (E-250, L-deprenyl, selegiline), synthezised by Zoltan Ecseri in 1962, patented as antidepressant in 1965, 1966 and developed by Jozsef Knoll as \"psychic energizer ([@B75]).\" The combination of selegilines selective MAO-B-I properties and the short-lasting stimulant effect of one of its metabolites, metamphetamine, (later proved to be also a reversible MAO-inhibitor see also [@B52] for details of such early developments) was indeed a concept to put forward new antidepressant agents ([@B150]). Knoll mentioned in his 1965 publication that selegiline does not increase motility and lowers blood pressure in experimental animals. Using tyramine (a MAO-A and -B substrate) it became evident that selegiline antagonizes the socalled \"cheese-effect\" (increase of blood pressure noteable especially after consumption of larger amounts of cheese in patients treated with unselective or MAO-A-inhibitors) ([@B76]). As dopamine in rodent brain is s preferred MAO-A substrate an effect of MAO-inhibitors on motility (see above) has not been observed. PD, therefore, was not the focus for using MAO-B-I as therapeutic strategy. The suggestion in late 1974 for selegilines use in PD and especially in treating ON-OFF symptoms by one of use (PR) was based on (1) the early and in principle beneficial effects of MAO-I when combined with L-DOPA (see above), (2) the effects of selegiline in antagonizing the cheese-effect and (3) the possibility that dopamine in humans might well be a substrate for MAO-B. Convincing Moussa Youdim about using selegiline for a first trial in PD patients in PD he agreed to provide Walther Birkmayer and myself (P.R.) with some grams of selegiline that he had obtained from Josef Knoll. The trial was showing a beneficial effect in the symptomology of PD ([@B22]; [@B21]; [@B52]; for historical notes see [@B126]; [@B159]). Later ([@B19]; [@B20]) we provided evidence for selegiline having neuroprotective action, a concept that is still followed and seems to be proven by the follow-up propargylaminoderivative rasagiline as shown recently in the ADAGIO-study ([@B103]; [@B104]).

The innovating basic research and beneficial actions of selegiline in PD were responsible for intensive MAO-I drug developments for both PD and \"depression\". In this review we present the major compounds currently being used as well as an outlook of further such developments.

MAO-I in clinical practise
--------------------------

Monoamine oxidase (MAO) inhibitors (MAOIs) at present can be classified into 3 types:

Older, irreversible nonselective agents such as phenelzine and tranylcypromineIrreversible, selective drugs (MAO-B-I\'s) such as selegiline and rasagilineReversible, selective MAO-A inhibitors (RIMAs = reversible inhibitors of MAO-A) such as moclobemide (Overviews: [@B146]; [@B84])

The clinical indications and efficacy of the MAOIs are established for disorders as follows:

Parkinson\'s disease (PD)Depressive disordersAnxiety disorders (social phobia, panic disorder, PTSD)

Other potential therapeutic uses and indications can be smoking cessation, attention deficit hyperactivity disorder and cognitive deficits in dementia for moclobemide ([@B29]; [@B11]).

INDICATIONS IN PARKINSON\'S DISEASE
===================================

Treatment of motor symptoms
---------------------------

Both, **selegiline** and **rasagiline** ([Table 1](#T1){ref-type="table"}) are beneficial in treating motor symptoms in PD as monotherapy and in combination with L-DOPA and a decarboxylase inhibitor. Rasagiline is more effective in this regard as shown also in the daily dosis necessary for a symptomatic effect: 5\~10 mg/day selegiline, 1 mg/day rasagiline. Long-term trials with selegiline point to the fact that 30\~40% of the daily L-DOPA dosis can be spared when combined with the MAO-B-I ([@B146]; [@B85]; [@B94]). It is not far-fetched to assume, that PEA, which increases after selegiline treatment in brain tissue ([@B124]) and by this exerts dopamine release-promoting properties, contributes to dopamine\'s behavioural effects including improvement of motility ([@B52]; [@B59]; [@B127]).

There is overwhelming evidence that selegiline has beneficial effects on motoricity and motorfluctuations as shown already in the first clinical trial ([@B22]) and in follow-up clinical studies as summarized by Gerlach et al. ([@B59]).

**Rasagiline** effects on motoricity are even stronger as shown by the TEMPO- ([@B108]; [@B107]), PRESTO- ([@B109]), LARGO- ([@B119]) and ADAGIO- ([@B103]; [@B104]) studies.

In all these and additional clinical studies (eg [@B117]; [@B148]; [@B118]; [@B15]; [@B143]) it could be shown that rasagiline is well tolerated, safe, improves motor symptoms, prevents motor complications in PD, has beneficial effects on quality of life parameters, is effective as monotherapy or in adjunctions to L-DOPA-therapy, is beneficial in early and late stages of PD, is safe when combined with all other PD-relevant therapies including COMT-inhibitors and may have disease-modifying properties.

Neuroprotection and disease-modification
----------------------------------------

Selegiline and rasagiline are \"suizide-inhibitors\" which inhibit the enzyme irreversibly and for a rather long time. Therefore only newly synthesized enzyme will recover MAO activity sufficient to metabolize its substrates in an adequate amount. Positron-emission tomography (PET) studies have shown a biological half-life time (HLT) of MAO-B recovery after selegiline- ([@B54]) or rasagiline- ([@B57]) induced blockade of about 30\~40 days. As described earlier ([@B129]; [@B59]) PET-studies are only in part suitable to detect the HLT of MAO-inhibitors as they only detect the distribution of radiolabeled inhibitor and its metabolites. In addition the exact kinetic properties underlying these PET-studies have been described only at random ([@B3]). In contrast, measurement of PEA, the pure MAO-B substrate, in the urine of healthy individuals after selegiline dosing showed recovery (decline) of this amine concentration to normal values already 2\~3 days after withdrawal of selegiline ([@B34]). Such data agree with other pharmacological studies as described by Riederer and Lachenmayer ([@B130]) and point to the conclusion that the HLT of MAO-B recovery after irreversible inhibition by selegiline is about 7 days. According to Green et al. ([@B62]) an 80% inhibition of MAO-isoenzymes is necessary to increase concentration of biogenic amines significantly. This means that newly synthesized enzyme in the range of 20 to 30% is sufficient to lose any symptomatic behavioural effect after withdrawal of any MAO-inhibitor. In line with this are studies by Youdim and Tipton ([@B162]) who could not detect selegiline-induced stereotyped behaviour due to PEA increase 4 days after withdrawal of selegiline. At this time MAO-B recovery was already 20%. Taking these findings into account a wash-out phase of two weeks or after selegiline/rasagiline withdrawal is sufficient to avoid any symptomatic effect of these MAO-I\'s. Therefore, the interpretations of the DATATOP-study and other follow-up trials to demonstrate a \"neuroprotective\" effect have to be reconsidered. If so, a neuroprotective effect of selegiline cannot be excluded ([@B130]; [@B59]). [Table 2](#T2){ref-type="table"} (taken in part from Riederer and Lachenmayer 2003 with permission) illustrates the major outcomes of the most important clinical long-term trials with selegiline. While treatment of patients in an early phase of PD with selegiline shows sufficient results regarding motoricity and disease-modification the unconclusive results of the DATATOP-follow-up clinical trials may demonstrate a bias in severity of patients grouping as given in the first follow-up study ([@B113]) or that the patients have non-response based on disease-progression and/or accompanying diseases ([Table 3](#T3){ref-type="table"}). As there were no final conclusions about the neuroprotective effect of selegiline the development of more efficient clinical trial designs have been investigated including PET-controlled studies as shown with dopaminergic agonists. More recently the \"delayed-start study design\" has been developed as discussed by D\'Agostino ([@B38]). Rasagiline has been the first drug tested in such clinical trial. In fact the ADAGIO-study has given profound evidence for a disease-modifying effect of 1 mg/day rasagiline, while there was not such benefit at a 2 mg/day dosis ([Table 4](#T4){ref-type="table"}). Although - and in comparison to the negative outcome of a delayed-start-study with pramipexol ([@B140]) - there is ample evidence for a significant disease-modification with low dosis rasagiline this clinical outcome has been questioned recently ([@B1]; [@B137]; [@B141]). Caslake et al. ([@B28]) conclude in their Cochrane Database report: \"MAO-B inhibitors are one option for the early treatment of PD although they have weaker symptomatic effects than levodopa and dopamine agonists. They may reduce the rate of motor fluctuations compared with initial levodopa therapy and may have fewer significant adverse effects than the older agonists but data are too few to provide reliable conclusions\".

Neuroprotective, neurorestaurative and disease-modifying effects of selegiline and rasagiline are substantiated by in vitro-as well as in vivo experimental studies ([Table 5](#T5){ref-type="table"}). There is ample evidence that compounds attached to a propargylamino group induce molecular processes which act against cell death mechanisms like apoptosis, excitotoxicity and oxidative stress. These are non-MAO based mechanisms and they act not only on a functional level but rather on influencing gene expression and protein synthesis. These more recent discoveries are in line with the earlier assumption of neuroprotective/neurorestaurative/disease-modifying properties especially of this chemical class of compounds.

Depression in PD
----------------

With a prevalence of approximately 40% depression is considered to be the most frequent psychiatric manifestation in PD ([@B25]; [@B90]; [@B151]). Particular clinical features of the depressive symptom profile in patients with PD have been described ([@B154]; [@B23]) and recommendations towards better recognition given ([@B25]). About 50% of the patients meet the criteria for major depressive disorder (MDD), 50% have minor depression or dysthymia ([@B30]). Depression in PD is associated with increased disability and reduced quality of life, the impact of depressive symptoms in early PD especially should not be underestimated ([@B120]).

MAOIs in depression
-------------------

While early studies suggested that MAOIs were not as effective as other antidepressants, more recent studies have demonstrated that, when prescribed in adequate dosages, phenelzine and tranylcypromine are as effective as other antidepressants ([@B106]). [Table 6](#T8){ref-type="table"} gives a summary of important controlled studies with tranylcypromine. In a recent study tranylcypromine, 60 mg daily, was found effective in the treatment of panic disorder and social anxiety disorder comorbidity ([@B99]).

The main indications for the classical irreversible MAOIs are subgroups of depression such as atypical depression, dysthymia or for patients who do not respond to reuptake inhibitors, so-called therapy resistant depressions ([@B101]; [@B114]; [@B9]).

The therapeutic efficacy of moclobemide has been assessed in numerous controlled studies comparing it with placebo and established antidepressants (for reviews see [@B81]; [@B51]; [@B58]; [@B82]). An overview of the most relevant trials is given in [Table 7](#T9){ref-type="table"}.

Large trials in patients with major depression have generally confirmed that the efficacy of moclobemide is equivalent to that of TCAs beside some negative studies. Moclobemide treatment was usually fixed up to 300, 400 or 600 mg/day. It should be noted, however, that the use of dosages of up to 900 mg/d has been established due to clinical experience nowadays particularly in patients with refractory depression ([@B63]). A meta-analysis of inpatient studies indicated that higher dosages (\>450 mg/day) of moclobemide are needed for full therapeutic effect in patients with severe depression ([@B2]).

Subgroup analyses of patients revealed moclobemide to be effective in patients with dysthymia or atypical depression especially ([@B87]).

Several trials have evaluated moclobemide alone or in combination with TCAs or SSRIs in the treatment of refractory depression ([@B5]) reporting positive results. These data are limited and great caution is necessary because of the potential to induce the serotonin syndrome when combining moclobemide with serotoninergic drugs.

Uncontrolled long term follow-up studies demonstrated continued effectiveness of moclobemide over the treatment period of 1 year with more than 60% of patients having continued response ([@B58]). The role of MAOIs in maintenance treatment of depression still has to evaluated ([@B72]).

MAO-B inhibitors like selegiline in high dosage have been used in therapy-refractory depressions probably due to non-selective MAO effects (see review [@B80]). Recently, transdermal selegiline has been approved and released in the USA for treatment of major depression with a target dose of 6 mg/24 hours. This dosage and application overcomes the MAO-B selectivity and leads to MAO-A inhibition, seen to be necessary for antidepressive effects. In several controlled studies selegiline transdermal system exhibited significant treatment effects on MDD including core depression symptoms, vegetative symptoms and motor retardation ([@B55]; [@B136]). A combination of selegiline and 5-hydroxytryptophan has been tested in a pilot study and proved antidepressant efficacy ([@B91]).

Treatment with antidepressants and MAOIs in PD
----------------------------------------------

The scientific knowledge about the treatment with antidepressant drugs among PD patients is nearly missing. A pharmaco-epidemiological study in Danmark showed that persons treated with antiparkinson drugs have higher frequency of antidepressant drug treatment than have controls ([@B24]). Most authors conclude, that recommendations for the optimal drug treatment of depression in PD are difficult to give ([@B25]). Serotonin selective reuptake inhibitors (SSRIs) are given frequently, the benefit of SSRI treatment in PD has not been established, however ([@B154]).

Thirty-seven patients with early PD have been treated successfully with tranylcypromine (TCP), parkinsonian symptoms improved slightly, follow-up after 1.5 years on average revealed only slight worsening ([@B46]). No other studies have been reported with TCP so far.

Ten patients with PD have been treated successfully with moclobemide vs. moclobemide with selegiline under tyramine restriction ([@B145]). Sufficient data allowing conclusions are missing.

Dosage and administration
-------------------------

The recommended initial dosage of tranylcypromine is 10\~20 mg/day, of moclobemide 300 to 450 mg/day, given in 2 to 3 divided doses. Subsequent dosage increase to a maximum of 60 mg/day, 900 mg/day respectively, are made as clinically indicated ([@B10]; [@B51]). Clinical experience and studies in the last years clearly have shown the necessity of higher dosage of moclobemide pointing out the lack of early sufficient dose-finding studies. Recommended daily doses of phenelzine are 30 to 90 mg, of isocarboxazid 30 to 60 mg, respectively.

Dietary restrictions are essential for tranylcypromine (tyramine-rich food), unnecessary for moclobemide taken at the end of a meal. A 2 week wash-out period is required for switching between tranylcypromine and other classes of antidepressants, not between moclobemide and other antidepressants.

In patients with severe hepatic impairment, tranylcypromine and moclobemide dosages should be reduced by one-third to one-half in such patients ([@B4]; [@B51]).

The target dose of selegiline transdermal (not released in Europe so far) is 6 mg/24 hours.

Tolerability and safety
-----------------------

The most frequent adverse effects of irreversible MAOIs are orthostatic hypotension, sleep disturbances and nervousness/agitation ([@B123]). The mostly limiting factor in the use of these MAOIs is the potential for dangerous interactions with tyramine-rich foods and sympathomimetic and serotoninergic substances. Therefore, prescription is only possible to patients being strongly compliant with dietary restrictions. In the case of RIMAs like moclobemide there is no need for dietary restrictions. For \"selegiline transdermal system\" tyramine dietary restrictions are not needed. The incidence of the most frequently reported adverse effects from patients receiving MAOIs are summarised in [Table 7](#T9){ref-type="table"}.

Insomnia and impotency in men have been the most frequent side effects of TCP in patients with early PD ([@B46]).

Unlike nonselective, irreversible MAOIs and tricyclics, moclobemide has little effect on the cardiovascular system and lacks anticholinergic properties associated with TCAs ([@B92]; [@B58]). In almost all controlled clinical studies comparing moclobemide with TCAs moclobemide showed clearly superior tolerability ([@B152]; [@B51]; [@B58]). Headache, insomnia and agitation were the only one side effects being reported more frequently with moclobemide compared to re-uptake inhibiting antidepressants. Dizziness and nausea have been noticed additionally. No systematic changes in blood pressure were observed with moclobemide, whereas increases in both blood pressure and pulse were recorded for tranylcypromine ([@B83]). Body weight gain has been observed with phenelzine and isocarboxazid, no clearcut cases with tranylcypromine or moclobemide have been reported ([@B26]). Compared to SSRIs moclobemide showed fewer gastrointestinal adverse effects and sexual dysfunction have not been reported with moclobemide ([@B115]).

Regarding cognitive functions data in favour of moclobemide compared to other antidepressants are available: Behavioural toxicity assessed by choice reaction time is very low or missing, psychomotor functions seem not be influenced negatively perhaps even improved ([@B70]).

The principal side effects of selegiline transdermal were local dermal reactions and (dose-related) insomnia ([@B135]).

After ingestion of up to 20 g of moclobemide no fatalities were observed, so moclobemide can be considered as a \'safe\' antidepressant ([@B40]; [@B31]). Several fatal overdoses have been reported when moclobemide was combined with serotoninergic antidepressants like citalopram, clomipramine or fluoxetine due to occurrence of a serotonin syndrome ([@B100]). In contrast, irreversible MAOIs like tranylcypromine must be regarded as less safe regarding to the fatal toxicity index ([@B69]).

Side effects of selegiline and rasagiline
-----------------------------------------

**Selegiline** is well tolerated. Side effects/adverse reactions like sleeplessness, nausea, vomiting, dizziness, dry mouth, orthostatic hypotension and dyskinesias have been all observed in the range of 2\~5% of PD patients ([@B111]; [@B121]) which is comparable to placebo. Other side effects like headache, heart beating, dyspnoe, edema, confusion, micturition dysfunction, loss of appetite and anxiety are even more rare and below 2% ([@B121]).

### Rasagiline

Adverse reactions as seen with other dopaminergic drugs, like nausea, vomiting, orthostatic hypotension, somnolence, hallucinations and dyskinesias are tolerable in most cases. Vomiting was noteable at 1 mg/day in the PRESTO-study, as was the occurrence of dyskinesias but such adverse reactions have not been described in other clinical trials like the LARGO-trial. Cognitive and behavioural symptoms of PD are not changed/worsened at 1 mg/day rasagiline ([@B43]).

Although interactions may be suggested when MAO-B inhibitors are combined with COMT-inhibitors, such adverse reactions have not been reported to be of relevance. In fact rasagiline is effective and well tolerated in PD patients with L-DOPA induced motor fluctuations receiving entacapone ([@B43]).

The cardiovascular risk in selegiline and rasagiline treated PD
---------------------------------------------------------------

**Selegiline** is metabolized mainly to desmethylselegiline, L-amphetamine and L-metamphetamine. Given these facts there was always a profound discussion about the contribution of these metabolites to selegiline\'s clinical symptomatic effects ([@B124]; [@B45]) and selegilines adverse reactions, predominantly of cardiovascular origin ([@B33]). L-Amphetamine has about a ten times lower activity on the peripheral sympathetic system compared to D-amphetamine. On the other hand, both are equipotent in blocking striatal dopamine uptake ([@B37]). A clinical trial of daily 10 mg selegiline vs. the calculated dosis and ratio of L-amphetamine and L-metamphetamine in PD patients came to the conclusion that selegiline did show antiakinetic efficacy while the metabolites did not ([@B45]). Therefore, selegiline is not acting via the amphetamine metabolites. Also, from the side effect profile as reported in the large selegiline based trials there is no evidence for enhanced cardiovascular risk (eg. [@B110]; [@B111]). This holds true also when selegiline is compared to treatment based on L-DOPA and dopaminergic receptor agonists. However, head-to head comparison is missing.

Nevertheless, to avoid further such discussion a sublingual galenic form of selegiline treatment has been developed named Zydis-selegiline ([@B35]; [@B36]). This \"melting-tablet\" avoids a first-pass effect and therefore a significant break-down to L-amphetamine and L-metamphetamine in the range of 90%. A reduction of the daily dosis of 10 mg selegiline to 1, 25 mg selegiline is advised. The bioavailability of selegiline when given as \"melting-tablet\" is more homogene and better reproduceable compared to the peroral type of application ([@B35]; [@B36]). In addition a transdermal galenic form of selegiline has been developed for the treatment of major depression again reducing selegilines first-pass biotransformation ([@B55]; [@B136]).

Melting tablet and transdermal selegiline avoid first-pass metabolism, cause higher drug availability in MAO-B preferring organs and reduce the concentration of metabolites. Increased drug concentration may cause significant inhibition of both MAO-B and -A in brain but not in the periphery. This explains selegilines antidepressant activity when combined with 5-hydroxytryptophan without the cheese-effect and without the serotonin syndrome ([@B91]).

Under clinical conditions selegiline is not more \"toxic\" than other dopaminergic treatment strategies. In fact the side effect and adverse reaction profile of selegiline has been evaluated as being well tolerated and \"mild\" compared to other PD treatment strategies, eg. orthostatic reactions have been noteable in only 3, 7% of patients ([@B121]).

It should be mentioned that L-amphetamine is in clinical use for the treatment of attention-deficit-hyperactivity syndrome (ADHD) without major side effects. In line with this are several studies as summarized by Reidenberg ([@B122]) showing no abuse liability of selegiline.

The contribution of desmethylselegiline (DMS) to the effects of selegiline has been underestimated so far. DMS is a weak inhibitor of MAO-B and seems to have glutathione related properties ([@B65]; [@B66]).

In contrast to selegiline, **rasagiline** is not metabolized to amphetamine. The main metabolite of rasagiline is aminoindan. Therefore any cardiovascular responses of rasagiline are neglectible as shown in animal studies ([@B48]) and in all clinical trials including the TEMPO- ([@B108]), PRESTO- ([@B109]), LARGO- ([@B119]) and ADAGIO-study ([@B103]; [@B104]).

In the recommended therapeutic dosis of 1 mg/day rasagiline does not potentiate the tyramine induced cheese-effect ([@B41]). This is in agreement with earlier findings in rats and cats ([@B50]; [@B32]; [@B48]).

Drug interactions
-----------------

Coadministration of SSRIs and other serotoninergic substances to tranylcypromine is contraindicated due to the risk of serotonin syndrome. With moclobemide great caution should be exercised with this combination. Severe, sometimes fatal, interactions between nonselective, irreversible MAOIs, moclobemide as well as selegiline and pethidine and dextromethorphan have been reported. Indirectly acting sympathomimetics (tyramine, ephedrine, pseudoephedrine) should be administered with caution in patients treated with MAOIs ([@B42]).

The elimination of moclobemide is significantly reduced by cimetidine making dose adjustment necessary.

Although selegiline has been reported to have antidepressant actions when combined with 5-hydroxytryptophan ([@B91]) MAO-B-inhibitors may not be safe enough to avoid the \"serotonin-syndrome\" when given in adjunct to serotonin-reuptake inhibitors (SSRIs) to treat depression and anxiety in PD patients. However, there is a low risk (0, 24%) to develop the \"serotonin-syndrome\" in selegiline treated patients ([@B125]). Also the results of a small number of PD patients treated with tricyclics and SSRIs plus rasagiline in the TEMPO-, PRESTO- and LARGO-studies do not give evidence for the \"serotonin-syndrome\", the population incidence of serotonin toxicity in those patients has a 9, 5% probability of being less than 1, 2% ([@B105]; [@B93]). However, a clinical trial with a biostatistic power relevant to give a definite answer to the problem is missing. Therefore MAO-B inhibitors have not to be combined with drugs stimulating the serotoninergic system.

Meperidin plus selegiline has been reported to be dangerous as it causes severe hypertension ([@B163]).

Selegiline transdermal without tyramine restriction revealed no acute hypertensive reactions in trials, until more data are available, foods that are rich sources of tyramine should be avoided, however.

As described by Chen and Swope ([@B32]) CYP1A2 inhibitors (cimetidine, fluvoxamine, ciprofloxacin) increase the area under curve of rasagiline, while CYP1A2 inducers like omeprazol decrease it, as it may decrease in heavy smokers.

Minor time-dependent mechanism-based inhibition of CYP2D6 has been described for selegiline and moclobemid in experimental designs; the significance in human beings remains to be investigated ([@B116]). For selegiline interactions with CYP 3A4 and CYP 2E1 may be relevant too.

Expert commentary
-----------------

While selective MAO-B-inhibitors demonstrate a significant benefit in PD and improve motoricity and motor fluctuations eventually causing disease-modification in general MAOIs to date play a subordinate therapeutic role in the treatment of depression in PD compared to SSRIs or reboxetine, a selective noradrenergic reuptake inhibitor. This attitude is primarily due to the risk of adverse effects and compliance problems (e.g. dietary restrictions, interaction problems) with MAOIs. Moclobemide according to its favourable adverse effect, interaction and toxicity profile can be used in depressed Parkinson patients when activating properties are necessary, especially.

Overall, the clinical use of MAOIs may be limited by the possible adverse effects of restlessness and insomnia - but see rasagiline. As far as long term and prophylactic treatments are concerned, the place of MAOIs still has to be verified as antidepressant or antidementive drugs in PD ([@B147]; [@B139]; [@B47]; [@B144]; [@B43]; [@B27]). Controlled studies are urgent needed for final evaluation and recommendations.

Five-year view
--------------

It would be worthwile to perform clinical studies to demonstrate the capacity of MAO-B inhibitors as antidepressants and antidementive drugs. New substances like ladostigil (MAOA/B inhibitor; AchE-inhibitor) or M30 and HLA-20 (MAO-A/B inhibitor, iron-chelator) and M30P (MAO-A/B inhibitor, carbonate cholinesterase inhibitor) give future aspects of using MAO-I\'s in a variety of clinical indications ([@B153]). The pharmacological properties of aminoindan have to be elucidated as they may be neuroprotective ([@B8]).

Key issues
----------

Head-to-head clinical trials are necessary to demonstrate disease-modification using improved delayed-start-study designs with selegiline and rasagiline. Otherwise no objective comparison can be made between the neuroprotective/neurorestaurative properties of selegiline and rasagiline.

Aminoindan has to be tested in vivo in order to get insight into its anti-parkinsonian efficacy.

The many molecular biological and -genetic data evolved from in-vitro studies have to be confirmed in in-vivo experiments to prove relevance in human beings. That other MAO-Is, even reversible ones might well be important in neuroprotection/disease modification is a just ongoing important issue. In addition, the respective role of MAO-A has to be elucidated in more detail.
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Monoamine oxidase inhibitors
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As reviewed by [@B89]; [@B154]; [@B99].
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Nueroprotection in Parkinson\'s disease by selegline (prospective, randomized, double-blind, placebo-controlled studies)
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From Riederer and [@B131].
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Datatop follow-up-clinical studies
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Summary of rasagiline clinical studies
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^\*^All studies were randomised, multi-centre, parallel-group and double-blind.

ADL: activities of daily living, CGI: clinical global impressions scale, LARGO: lasting effect in adjunct therapy with rasagiline given once daily, OFF: poor symptom response, ON: good symptom reponse, PD-QUALIF: parkinson\'s disease quality of life, PRESTO: Parkinson\'s rasagiline efficacy and safety in the treatment of OFF, TEMPO: trial of etanercept and methotrexate with radiographic patient outcomes, UPDRS-ADL: unified parkinson\'s disease rating scale-activities of daily living. From [@B119].
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Actions of propargylamine derived MAO-B-I
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As reviewed by [@B89], [@B154], [@B99].

###### 

Non-MAO related actions of selegiline and rasagiline on molecular paramters *in vitro*
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As reviewed by [@B89], [@B154], [@B99].

###### 

Non-MAO related actions of selegiline and rasagiline on molecular parameters *in vivo*
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As reviewed by [@B89], [@B154], [@B99].

###### 

Randomised, double-blind controlled studies with tranylcypromine (TCP) in the treatment of depressive disorders (from [@B83])
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Legend: =indicates equivalent to, \>indicates more effective than references in this table are given in detail in [@B83].

###### 

Randomised, double-blind controlled studies with moclobemide (M) in the treatment of depressive disorders (selection; references see [@B59]; [@B83])
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C: comparator, =indicates equivalent to, \>indicates more effective/better tolerated than. ^\*^melancholic subtype.
